3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Motor Activity
9
Neoplasms
4
Colorectal Neoplasms
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Obesity
3
Breast Neoplasms
3
Brain Neoplasms
3
Sarcopenia
2
Multiple Myeloma
2
Weight Loss
1
Triple Negative Breast Neoplasms
1
Thrombocythemia, Essential
1
Smoldering Multiple Myeloma
1
Skin Neoplasms
1
Renal Insufficiency, Chronic
1
Rehabilitation Exercise
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Overweight
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Melanoma
1
Lymphoma, B-Cell
1
Lymphoma
1
Lymphedema
1
Lung Neoplasms
1
Locally Advanced Head and Neck Squamous Cell Carcinoma
1
Leukemia, Myeloid, Acute
1
Interventions
Cyclophosphamide
47
Rituximab
31
fludarabine
29
Specimen Handling
13
Magnetic Resonance Spectroscopy
13
Doxorubicin
13
pirtobrutinib
11
Vincristine
11
Prednisone
11
fludarabine phosphate
10
Immunotherapy, Adoptive
10
Etoposide
10
Bendamustine Hydrochloride
10
obinutuzumab
8
Lenalidomide
8
Biopsy
8
venetoclax
7
polatuzumab vedotin
7
glofitamab
7
zanubrutinib
6
pembrolizumab
6
Dexamethasone
6
tafasitamab
5
ibrutinib
5
etoposide phosphate
5
acalabrutinib
5
Leukapheresis
5
tazemetostat
4
loncastuximab tesirine
4
Nivolumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, B-Cell
×
Resistance Training
×
1 year
×
Clear all
NCT05556239
2025-12-08
STAY-STRONG
Rigshospitalet, Denmark
Phase NA
Completed
42 enrolled